L-T4 Therapy in Enteric Malabsorptive Disorders.


Journal

Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782

Informations de publication

Date de publication:
2021
Historique:
received: 05 11 2020
accepted: 13 01 2021
entrez: 12 3 2021
pubmed: 13 3 2021
medline: 18 12 2021
Statut: epublish

Résumé

Levothyroxine (L-T4) absorption can be impaired by various causes: a) L-T4 ingestion during breakfast, or with food; b) conditions of reduced gastric acidity; c) intestinal procedures and diseases such as bariatric surgery, lactose intolerance (LI), celiac disease (CD), inflammatory bowel disease; d) drugs that alter L-T4 absorption, increasing the gastric pH, or preventing the dissolution of tablets. The development of new oral formulations, i.e. the liquid preparation and the soft gel capsule, represents the most recent advance regarding L-T4 therapy. Treating hypothyroidism with L-T4 tablets can lead to an improper control of thyroid-stimulating hormone (TSH) in ~10%-15% of patients. The improperly elevated TSH is usually managed by increasing the L-T4 daily dose, and revaluating TSH upon 2-6 months. The increase of the L-T4 dosage may cause iatrogenic hyperthyroidism, especially when the underlying disorders are cured. Liquid L-T4 can be administered in patients unable to swallow capsules or tablets, and this is one of its major benefits. Liquid L-T4 can: 1- overcome food and beverages interference; 2- bypass the malabsorption associated with an increased gastric pH; 3- circumvent the issue of malabsorption in patients who underwent bariatric surgery; 4-maintain TSH values under control better than L-T4 tablets in hypothyroid patients with typical or atypical CD, or in patients with LI. Few clinical studies evaluated soft gel L-T4 with encouraging findings in patients with gastric- or coffee-related malabsorption, or hypothyroid patients without malabsorption. Additional research is necessary to investigate liquid L-T4, or soft gel capsule, in other conditions of altered L-T4 absorption.

Identifiants

pubmed: 33708175
doi: 10.3389/fendo.2021.626371
pmc: PMC7940821
doi:

Substances chimiques

Thyroxine Q51BO43MG4

Types de publication

Journal Article Research Support, Non-U.S. Gov't Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

626371

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2021 Fallahi, Ferrari, Elia, Ragusa, Paparo and Antonelli.

Déclaration de conflit d'intérêts

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The handling editor declared a past co-authorship with several of the authors: AA, FR, GE, PF, SMF, and SRP.

Références

Laryngoscope Investig Otolaryngol. 2018 Oct 03;3(5):405-408
pubmed: 30410995
J Clin Endocrinol Metab. 2008 Feb;93(2):465-9
pubmed: 18042648
Autoimmun Rev. 2014 Apr-May;13(4-5):391-7
pubmed: 24434360
Endocrine. 2015 May;49(1):51-7
pubmed: 25595886
J Clin Endocrinol Metab. 2014 Dec;99(12):4481-6
pubmed: 25259910
Expert Opin Drug Deliv. 2014 Jul;11(7):1103-11
pubmed: 24896369
Eur J Endocrinol. 2013 Nov 22;170(1):95-9
pubmed: 24123095
Thyroid. 2018 Apr;28(4):454-457
pubmed: 29589994
Endocrine. 2016 Jun;52(3):571-8
pubmed: 26537478
Eur J Intern Med. 2020 Jun;76:118-119
pubmed: 32094018
Expert Opin Drug Saf. 2014 Jun;13(6):723-33
pubmed: 24821006
Thyroid. 2016 Feb;26(2):197-202
pubmed: 26586610
Arzneimittelforschung. 2012 Dec;62(12):631-6
pubmed: 23154888
Clin Drug Investig. 2017 Jan;37(1):71-83
pubmed: 27798756
Drugs R D. 2017 Mar;17(1):103-115
pubmed: 27943146
Obes Surg. 2017 Jan;27(1):78-82
pubmed: 27272506
Horm Res Paediatr. 2014;81(1):50-4
pubmed: 24247169
Thyroid. 1995 Aug;5(4):249-53
pubmed: 7488863
Endocrine. 2017 Jan;55(1):6-18
pubmed: 27981511
Obes Surg. 2013 Sep;23(9):1493-6
pubmed: 23824980
Eur J Pharm Biopharm. 2009 May;72(1):105-10
pubmed: 18996189
Thyroid. 2013 Jul;23(7):779-84
pubmed: 23363386
Eur J Endocrinol. 2018 Jun;178(6):R231-R244
pubmed: 29490937
Endocrine. 2016 Jun;52(3):597-601
pubmed: 26721663
Endocrine. 2014 Jun;46(2):279-84
pubmed: 24078411
JAMA. 1983 Oct 21;250(15):2045-6
pubmed: 6352971
N Engl J Med. 2006 Apr 27;354(17):1787-95
pubmed: 16641395
J Clin Endocrinol Metab. 2014 Aug;99(8):E1454-8
pubmed: 24796930
Endocr Pract. 2014 Mar;20(3):e38-41
pubmed: 24246350
Endocrinol Diabetes Metab Case Rep. 2019 Mar 21;2019:
pubmed: 30897550
Ther Drug Monit. 2011 Jun;33(3):355-61
pubmed: 21516059
Autoimmun Rev. 2015 Feb;14(2):174-80
pubmed: 25461470
Endocrine. 2018 Feb;59(2):458-460
pubmed: 28466401
Front Endocrinol (Lausanne). 2018 Mar 21;9:118
pubmed: 29619010
Eur J Intern Med. 2015 Dec;26(10):825-9
pubmed: 26423749
Endokrynol Pol. 2012;63(4):318-23
pubmed: 22933169
Nutrients. 2020 May 08;12(5):
pubmed: 32397091
Endocr Rev. 2019 Feb 1;40(1):118-136
pubmed: 30476027
J Clin Endocrinol Metab. 2012 Apr;97(4):1134-45
pubmed: 22278420
Thyroid. 2009 Nov;19(11):1167-214
pubmed: 19860577
Obes Rev. 2010 Jan;11(1):41-50
pubmed: 19493300
Endocrine. 2019 Oct;66(1):87-94
pubmed: 31617168
Gynecol Endocrinol. 2016;32(4):290-2
pubmed: 26585420
J Thyroid Res. 2011;2011:809341
pubmed: 21760981
World J Gastroenterol. 2014 Aug 14;20(30):10331-7
pubmed: 25132749
Aliment Pharmacol Ther. 2009 Jun 15;29(12):1219-29
pubmed: 19302263
Expert Opin Drug Deliv. 2017 May;14(5):647-655
pubmed: 27552635
Endocrine. 2013 Feb;43(1):154-60
pubmed: 22932947
J Endocrinol Invest. 2017 Dec;40(12):1289-1301
pubmed: 28695483
BMC Gastroenterol. 2016 Feb 24;16:22
pubmed: 26965518
Thyroid. 2008 Mar;18(3):293-301
pubmed: 18341376
J Clin Endocrinol Metab. 2012 Mar;97(3):E419-22
pubmed: 22238404
Parasite. 2008 Sep;15(3):261-5
pubmed: 18814692
Endocrine. 2017 Jul;57(1):175-178
pubmed: 27577569
Endocrine. 2017 Sep;57(3):394-401
pubmed: 27848196
Endocrine. 2018 Jul;61(1):28-35
pubmed: 29572710
AAPS PharmSciTech. 2010 Sep;11(3):1359-67
pubmed: 20740332
Ann Clin Biochem. 2016 Jul;53(Pt 4):421-33
pubmed: 27126268
Arq Bras Endocrinol Metabol. 2011 Feb;55(1):81-4
pubmed: 21468525
Endocr Pract. 2017 Feb;23(2):170-174
pubmed: 27849377
Best Pract Res Clin Endocrinol Metab. 2019 Dec;33(6):101367
pubmed: 31812326
Front Endocrinol (Lausanne). 2018 Jan 26;9:10
pubmed: 29434573
Front Endocrinol (Lausanne). 2017 Mar 20;8:50
pubmed: 28373861
Front Endocrinol (Lausanne). 2017 Nov 20;8:321
pubmed: 29209276
Front Endocrinol (Lausanne). 2017 Apr 26;8:92
pubmed: 28491051
J Clin Endocrinol Metab. 2009 Oct;94(10):3905-12
pubmed: 19584184
J Endocrinol Invest. 2014 Jun;37(6):583-7
pubmed: 24789541
Clin Ther. 2017 Feb;39(2):378-403
pubmed: 28153426

Auteurs

Poupak Fallahi (P)

Department of Translational Research of New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.

Silvia Martina Ferrari (SM)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Giusy Elia (G)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Francesca Ragusa (F)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Sabrina Rosaria Paparo (SR)

Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

Alessandro Antonelli (A)

Department of Surgical, Medical and Molecular Pathology and Critical Care, University of Pisa, Pisa, Italy.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH